Cargando…
Oral Semaglutide: Dosage in Special Situations
Glucagon-like peptide 1 receptor agonists (GLP1RAs) have recently gained momentum after the introduction of semaglutide, the first oral molecule in their class. In a recent article in this journal by Evans et al., a succinct overview of the utility of semaglutide is highlighted in the context of vir...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174361/ https://www.ncbi.nlm.nih.gov/pubmed/35532859 http://dx.doi.org/10.1007/s13300-022-01265-5 |
_version_ | 1784722222963752960 |
---|---|
author | Kalra, Sanjay Kapoor, Nitin |
author_facet | Kalra, Sanjay Kapoor, Nitin |
author_sort | Kalra, Sanjay |
collection | PubMed |
description | Glucagon-like peptide 1 receptor agonists (GLP1RAs) have recently gained momentum after the introduction of semaglutide, the first oral molecule in their class. In a recent article in this journal by Evans et al., a succinct overview of the utility of semaglutide is highlighted in the context of virtual diabetes care. To take this discussion further, this commentary describes the value and positioning of oral semaglutide in common clinical situations. Its insights assist in pragmatic placement of this drug in clinical practice. Special emphasis is laid on the use of oral semaglutide in persons already on injectable GLP-1RA formulations, those experiencing sudden changes in life style pattern due to religious, social, or professional commitments, individuals seeking help for urgent glycemic control, and those who face sudden change in their concomitant medications or comorbidities. |
format | Online Article Text |
id | pubmed-9174361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-91743612022-06-09 Oral Semaglutide: Dosage in Special Situations Kalra, Sanjay Kapoor, Nitin Diabetes Ther Commentary Glucagon-like peptide 1 receptor agonists (GLP1RAs) have recently gained momentum after the introduction of semaglutide, the first oral molecule in their class. In a recent article in this journal by Evans et al., a succinct overview of the utility of semaglutide is highlighted in the context of virtual diabetes care. To take this discussion further, this commentary describes the value and positioning of oral semaglutide in common clinical situations. Its insights assist in pragmatic placement of this drug in clinical practice. Special emphasis is laid on the use of oral semaglutide in persons already on injectable GLP-1RA formulations, those experiencing sudden changes in life style pattern due to religious, social, or professional commitments, individuals seeking help for urgent glycemic control, and those who face sudden change in their concomitant medications or comorbidities. Springer Healthcare 2022-05-07 2022-06 /pmc/articles/PMC9174361/ /pubmed/35532859 http://dx.doi.org/10.1007/s13300-022-01265-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Commentary Kalra, Sanjay Kapoor, Nitin Oral Semaglutide: Dosage in Special Situations |
title | Oral Semaglutide: Dosage in Special Situations |
title_full | Oral Semaglutide: Dosage in Special Situations |
title_fullStr | Oral Semaglutide: Dosage in Special Situations |
title_full_unstemmed | Oral Semaglutide: Dosage in Special Situations |
title_short | Oral Semaglutide: Dosage in Special Situations |
title_sort | oral semaglutide: dosage in special situations |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174361/ https://www.ncbi.nlm.nih.gov/pubmed/35532859 http://dx.doi.org/10.1007/s13300-022-01265-5 |
work_keys_str_mv | AT kalrasanjay oralsemaglutidedosageinspecialsituations AT kapoornitin oralsemaglutidedosageinspecialsituations |